Poliovirus recombinants against malignant glioma

Viral Therapy of Human Cancers

Volumn , Issue , 2004, Pages 739-780

  Merrill, Melinda ^a   Solecki, David ^b   Gromeier, Matthias ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 59849118055     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (109)

1. Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily Cell 1989; 56:855-865.
2. He Y, Bowman VD, Mueller S, Bator CM, Bella J, Peng X, Baker TS, Wimmer E, Kuhn RJ, Rossmann MG. Interaction of the poliovirus receptor with poliovirus Proc Natl Acad Sci U S A 2000; 97:79-84.
3. Nomoto A, Lee YF, Wimmer E. The 5′ end of poliovirus mRNA is not capped with m7G(5′)ppp(5′)Np Proc Natl Acad Sci U S A 1976; 73:375-380.
4. Lee YF, Nomoto A, Detjen BM, Wimmer E. A protein covalently linked to poliovirus genome RNA Proc Natl Acad Sci U S A 1977; 74:59-63.
5. Jang SK, Kraeusslich HG, Nicklin MJ, Duke GM, Palmenberg AC, Wimmer E. Asegment of the 5′ nontranslated region of encephalomyocarditis virus RNA directs internal entry of ri- bosomes during in vitro translation J Virol 1988; 62: 2636-2643.
6. Pelletier J, Sonenberg N. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA Nature 1988; 334:320-325.
7. Etchison D, Milburn SC, Edery I, Sonenberg N, Hershey JW. Inhibition of HeLa cell protein synthesis following poliovirus infection correlates with the proteolysis of a 220,000-dalton polypeptide associated with eukaryotic initiation factor 3 and a cap binding protein complex J Biol Chem 1982; 257: 14806-14810.
8. Joachims M, Van Breugel PC, Lloyd RE. Cleavage of poly(A)- binding protein by enterovirus proteases concurrent with inhi- bition of translation in vitro J Virol 1999; 73:718-727.
9. Kerekatte V, Keiper BD, Badorff C, Cai A, Knowlton KU, Rhoads RE. Cleavage of Poly(A)-binding protein by coxsackie- virus 2A protease in vitro and in vivo: another mechanism for host protein synthesis shutoff? J Virol 1999; 73:709-717.
10. Le H, Tanguay RL, Balasta ML, Wei CC, Browning KS, Metz AM, Goss DJ, Gallie DR. Translation initiation factors eIF- iso4G and eIF-4B interact with the poly(A)-binding protein and increase its RNA binding activity J Biol Chem 1997; 272: 16247-16255.
11. Tarun SZ, Sachs AB. Association of the yeast poly(A) tail binding protein with translation initiation factor eIF-4G EMBO J 1996; 15:7168-7177.
12. Wells SE, Hillner PE, Vale RD, Sachs AB. Circularization of mRNA by eukaryotic translation initiation factors Mol Cell 1998; 2:135-140.
13. Sachs AB. Physical and functional interactions between the mRNA cap structure and the poly(A) tail. In: Sonenberg N, Hershey JWB, Matthews MB, Eds. Translational Control of Gene Expression. NY: Cold Spring Harbor Laboratory Press, 2000:447-466.
14. Gromeier M, Nomoto A. Determinants of poliovirus pathogenesis. In: Semler B, Wimmer E, Eds. The Molecular Biology of Picornaviruses. Washington, DC: ASM Press, 2002:426-443
15. Yang WX, Terasaki T, Shiroki K, Ohka S, Aoki J, Tanabe S, Nomura T, Terada E, Sugiyama Y, Nomoto A. Efficient delivery of circulating poliovirus to the central nervous system in- dependently of poliovirus receptor Virology 1997; 229: 421-428.
16. Ren R, Racaniello VR. Poliovirus spreads from muscle to the central nervous system by neural pathways J Infect Dis 1992; 166:747-752.
17. Gromeier M, Wimmer E. Mechanism of injury-provoked polio- myelitis J Virol 1998; 72:5056-5060.
18. Bodian D. Poliomyelitis. In: Minckler J, Ed. Pathology of the Nervous System. Vol. 3. New York: McGraw-Hill, 1972: 2323-2344.
19. Bellmunt A, May G, Zell R, Pring-Akerblom P, Verhagen W, Heim A. Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient Virology 1999; 265:178-184.
20. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5 Science 1997; 275:1320-1323.
21. Tomko RP, Xu R, Philipson L. HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses Proc Natl Acad Sci U S A 1997; 94: 3352-3356.
22. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents Nat Med 1997; 3:639-645.
23. Asaoka K, Tada M, Sawamura Y, Ikeda J, Abe H. Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the coxsackievirus and adenovirus receptor J Neurosurg 2000; 92:1002-1008.
24. Douglas JT, Kim M, Sumerel LA, Carey DE, Curiel DT. Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors Cancer Res 2001; 61:813-817.
25. Li D, Duan L, Freimuth P, O’Malley BW. Variability of adenovirus receptor density influences gene tranfer efficiency and therapeutic response in head and neck cancer Clin Cancer Res 1999; 5:4175-4181.
26. Li Y, Pong RC, Bergelson JM, Hall MC, Sagalowsky AI, Tseng CP, Wang Z, Hsieh JT. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy Cancer Res 1999; 59:325-330.
27. Merrill M, Sampson JH, Bernhardt G, Wikstrand C, Bigner DD, Gromeier M. Molecular targeting of the human poliovirus receptor CD155 in malignant glioma Neuro Oncology 2004; 6: 208-217.
28. Gromeier M, Solecki D, Patel D, Wimmer E. Expression of the human poliovirus receptor/CD155 gene during development of the CNS: implications for the pathogenesis of poliomyelitis Virology 2000; 273:259-268.
29. Eberle F, Duybreuil P, Mattei MG, Devilard E, Lopez M. The human PRR2 gene, related to the human poliovirus receptor gene (PVR) is the true homolog of the murine MPH gene Gene 1995; 159:267-272.
30. Lopez M, Eberle R, Mattei MG, Gabert J, Birg F, Bardin F, Maroc C, Dubreuil P. Complementary DNA characterization and chromosomal localization of a human gene related to the poliovirus receptor-encoding gene Gene 1995; 155:261-265.
31. Reymond N, Borg J, Lecocq E, Adelaide J, Campadelli-Fiume G, Dubreuil P, Lopez M. Human nectin3/PRR3: A novel mem- ber of the PVR/PRR/nectin family that interacts with afadin Gene 2000; 255:347-355.
32. Reymond N, Fabre S, Lecocq E, Adelaide J, Dubreuil P, Lopez M. Nectin4/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1/PRR1 through V domain interaction J Biol Chem 2001; 276:43205-43215.
33. Lopez M, Aoubala M, Jordier F, Isnardon D, Gomez S, Du- breuil P. The human poliovirus receptor related 2 protein is a new hematopoietic/endothelial homophilic adhesion molecule Blood 1998; 92:4602-4611.
34. Aoki J, Koike S, Asou H, Ise I, Suwa H, Tanaka T, Miyasaki M, Nomoto A. Mouse homolog of poliovirus receptor-related gene 2 product, mPRR2, mediates homophilic cell aggregation Exp Cell Res 1997; 235:374-384.
35. Tachibana K, Nakanishi H, Mandai K, Ozaki K, Ikeda W, Ya- mamoto Y, Nagafuchi A, Tsukita S, Takai Y. Two cell adhesion molecules, nectin and cadherin, interact through their cyto- plasmic domain-associated protein J Cell Biol 2000; 150: 1161-1176.
36. Takahashi K, Nakanishi H, Mihahara M, Mandai K, Satoh K, Satoh A, Nishioka H, Aoki J, Nomoto A, Mizoguchi A, Takai Y. Nectin/PRR: An immunoglobulin-like cell adhesion molecule recruited to cadherin-based adherens junctions through inter- action with afadin, a PDZ domain-containing protein J Cell Biol 1999; 145:539-549.
37. Miyahara M, Nakanishi H, Takahashi K, Satoh-Horikawa K, Tachibana K, Takai Y. Interaction of nectin with afadin is necessary for its clustering at cell-cell contact sites but not for its cis dimerization or trans interaction J Biol Chem 2000; 275:613-618.
38. Geraghty RJ, Krummenacher C, Cohen GH, Eisenberg RJ, Spear PG. Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor Science 1998; 280:1618-1620.
39. Koike S, Ise I, Sato Y, Yonekawa H, Gotoh O, Nomoto A. A second gene for the African green monkey poliovirus receptor that has no putative N-glycosylation site in the functional N- terminal immunoglobulin-like domain J Virol 1992; 66: 7059-7066.
40. Chadeneau C, LeCabellec M, LeMoullac B, Meflah K, Denis MG. Over-expression of a novel member of the immunoglobu- lin superfamily in Min mouse intestinal adenomas Int J Cancer 1996; 68:817-821.
41. Ren RB, Costantini F, Gorgacz EJ, Lee JJ, Racaniello VR. Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis Cell 1990; 63:353-362.
42. Koike S, Taya C, Kurata T, Abe S, Ise I, Yonekawa H, Nomoto A. Transgenic mice susceptible to poliovirus Proc Natl Acad Sci U S A 1991; 88:951-955.
43. Solecki D, Schwarz S, Wimmer E, Lipp M, Bernhardt G. The promoters from human and monkey poliovirus receptors J Biol Chem 1997; 272:5579-5586.
44. Solecki DJ, Wimmer E, Lipp M, Bernhardt G. Identification and characterization of the cis-acting elements of the human CD155 gene core promoter J Biol Chem 1999; 274:1791-1800.
45. Solecki DJ, Bernhardt G, Lipp M, Wimmer E. Identification of a nuclear respiratory factor-1 binding site within the core promoter of the human poliovirus receptor/CD155 gene J Biol Chem 2000; 275:12453-12462.
46. Solecki DJ, Gromeier M, Mueller S, Wimmer E, Bernhardt G. Expression of the human poliovirus receptor/CD155 gene is activated by Sonic Hedgehog J Biol Chem 2002; 277: 25697-25702.
47. Zhang J, Hagopian-Donaldson S, Serbedzija G, Elsemore J, Plehn-Dujowich D, McMahon AP, Flavell RA, Williams T. Neural tube, skeletal and body wall defects in mice lacking transcription factor AP-2 Nature 1996; 381:238-241.
48. Schorle H, Meier P, Buchert M, Jaenisch R, Mitchell PJ. Transcription factor AP-2 essential for cranial closure and craniofacial development Nature 1996; 381:235-238.
49. Becker TS, Burgess SM, Amsterdam AH, Allende ML, Hop- kins N. not really finished is crucial for development of the zebrafish outer retina and encodes a transcription factor highly homologous to human Nuclear Respiratory Factor-1 and avian Initiation Binding Repressor Development 1998; 125:4369-4378.
50. Tanabe Y, Jessell TM. Diversity and pattern in the developing spinal cord Science 1996; 274:1115-1123.
51. Hammerschmidt M, Brook A, McMahon AP. The world according to hedgehog Trends Genet 1997; 13:14-21.
52. Kalderon D. Transducing the hedgehog signal Cell 2000; 103: 371-374.
53. Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles Genes Dev 2001; 15: 3059-3087.
54. Goodrich LV, Milenkovic L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants Science 1997; 277:1109-1113.
55. Ruiz i Altaba A, Sanchez P, Dahmane N. Gli and hedgehog in cancer: tumours, embryos and stem cells Nat Rev Cancer 2002; 2:361-372.
56. Dahmane N, Sanchez P, Gitton Y, Palma V, Sun T, Beyna M, Weiner H, Ruiz i Altaba A. The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis Development 2001; 128:5201-5212.
57. Kinzler KW, Bigner SH, Bigner DD, Trent JM, Law ML, O’Brien SJ, Wong AJ, Vogelstein B. Identification of an amplified, highly expressed gene in a human glioma Science 1987; 236:70-73.
58. Izumoto S, Ohnishi T, Arita N, Hiraga S, Taki T, Hayakawa T. Gene expression of neural cell adhesion molecule L1 in malignant gliomas and biological significance of L1 in glioma in- vasion Cancer Res 1996; 56:1440-1444.
59. Sasaki H, Yoshida K, Ikeda E, Asou H, Inaba M, Otani M, Kawase T. Expression of the neural cell adhesion molecule in astrocytic tumors: an inverse correlation with malignancy Cancer 82:1921-1931.
60. Rickman DS, Rachana T, Xiao-Xiang Z, Bobek MP, Song S, Blaivas M, Misek DE, Israel MA, Kurnit DM, Ross DA, Kish PE, Hanash SM. The gene for the axonal cell adhesion molecule TAX-1 is amplified and aberrantly expressed in malignant glioma Cancer Res 2001; 61:2162-2168.
61. Sehgal A, Boynton AL, Young RF, Vermeulen SS, Yonemura KS, Koehler EP, Aldape HC, Simrell CR, Murphy GP. Cell adhesion molecule Nr-CAM is over-expressed in human brain tumors Int J Cancer 1998; 76:451-458.
62. Goldbrunner RH, Bernstein JJ, Tonn JC. Cell-extracellular matrix interaction in glioma invasion Acta Neurochir 1999; 141:295-305.
63. Johnson JP. Cell adhesion molecules in the development and progression of malignant melanoma Cancer Metastasis Rev 1999; 18:345-357.
64. Ohene-Abuakwa Y, Pignatelli M. Adhesion molecules in cancer biology Adv Exp Med Biol 2000; 465:115-126.
65. Taguchi A, Blood DC, Del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, In- gram M, Lu A, Tanak H, Hori O, Ogawa S, Stern DM, Schmidt AM. Blockade of RAGE-amphoterin signaling suppresses tumor growth and metastases Nature 2000; 405:354-360.
66. Masson D, Jarry A, Baury B, Blanchardie P, Laboisse C, Lus- tenberger P, Denis MG. Overexpression of the CD155 gene in human colorectal carcinoma Gut 2001; 49:236-240.
67. Lange R, Peng X, Wimmer E, Lipp M, Bernhardt G. The poliovirus receptor CD155 mediates cell-to-matrix contacts by specifically binding to vitronectin Virology 2001; 285:218-227.
68. Martinez-Morales JR, Barbas JA, Marti E, Bovolenta P, Edgar D, Rodriguez-Tebar A. Vitronectin is expressed in the ventral region of the neural tube and promotes the differentiation of motor neurons Development 1997; 124:5139-5147.
69. Martinez-Morales JR, Marti E, Frade JM, Rodriguez-Tebar A. Developmentally regulated vitronectin influences cell differentiation, neuron survival and process outgrowth in the developing chicken retina Neuroscience 1995; 68:245-253.
70. Pons S, Marti E. Sonic hedgehog synergizes with the extracellular matrix protein vitronectin to induce spinal motor neuron differentiation Development 2000; 127:333-342.
71. Gladson CL, Wilcox JN, Sanders L, Gillespie GY, Cheresh DA. Cerebral microenvironment influences expression of the vi- tronectin gene in astrocytic tumors J Cell Sci 1995; 108: 947-956.
72. Uhm JH, Dooley NP, Kyritsis AP, Rao JS, Gladson CL. Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death Clin Cancer Res 1999; 5:1587-1594.
73. Gromeier M. Viruses as therapeutic agents against malignant disease of the central nervous system J Natl Cancer Inst 2001; 93:889-890.
74. Gromeier M, Wimmer E. Viruses for the treatment of malignant glioma Curr Opin Mol Ther 2001; 3:503-508.
75. Gromeier M. Oncolytic viruses for cancer therapy Am J Cancer 2004:In press.
76. Wimmer E, Hellen CUT, Cao XM. Genetics of poliovirus Annu Rev Genet 1993; 27:353-436.
77. Alexander L, Lu HH, Wimmer E. Polioviruses containing pi- cornavirus type 1 and/or type 2 internal ribosomal entry site elements: genetic hybrids and the expression of a foreign gene Proc Natl Acad Sci U S A 1994; 91:1406-1410.
78. Lu HH, Wimmer E. Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry site of hepatitis C virus Proc Natl Acad Sci U S A 1996; 93: 1412-1417.
79. Gromeier M, Alexander L, Wimmer E. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants Proc Natl Acad Sci U S A 1996; 93:2370-2375.
80. Gromeier M, Bossert B, Arita M, Nomoto A, Wimmer E. Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence J Virol 1999; 73:958-964.
81. La Monica N, Racaniello VR. Differences in replication of attenuated and neurovirulent poliovirus in human neuroblas- toma cell line SH-SY5Y J Virol 1989; 63:2357-2360.
82. Agol VI, Drozdov SG, Ivannikova TA, Kolesnikova MS, Koro- lev MB, Tolskaya EA. Restricted growth of attenuated poliovirus strains in cultured cells of a human neuroblastoma J Virol 1989; 63:4034-4038.
83. Gromeier M, Lachmann S, Rosenfeld M, Gutin P, Wimmer E. Nonpathogenic intergeneric poliovirus recombinants for the treatment of glioma Proc Natl Acad Sci U S A 2000; 97: 6803-6808.
84. Macadam AJ, Ferguson G, Burlison J, Stone D, Almond JW. Correlation of RNA secondary structure and attenuation of Sabin vaccine strains of poliovirus in tissue culture Virology 1992; 189:415-422.
85. Skinner MA, Racaniello VR, Dunn G, Cooper J, Minor PD, Almond JW. New model for the secondary structure of the 5′ Non-coding RNA of poliovirus is supported by biochemical and genetic data that also shows that RNA secondary structure is important in neurovirulence J Mol Biol 1989; 207:379-392.
86. Christodoulou C, Colbere-Garapin F, Macadam A, Taffs LF, Marsden S, Horaud F. Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature J Virol 1990; 64: 4922-4929.
87. Pestova TV, Hellen CUT, Shatsky IN. Canonical eukaryotic initation-factors determine initation of tranlation by internal ribosomal entry Mol Cell Biol 1996; 16:6859-6869.
88. Hellen CUT, Witherell GW, Schmid M, Shin SH, Pestova TV, Gil A, Wimmer E. A cytoplasmic 57 kDa protein that is re- quired for translation of picornavirus RNA by internal ribo- somal entry is identical to the nuclear pyrimidine tract-binding protein Proc Natl Acad Sci U S A 1993; 90:7642-7646.
89. Meerovitch K, Svitkin YV, Lee HS, Lejbkowicz F, Kenan DJ, Chan EKL, Agol VI, Keene JD, Sonenberg N. La autoantigen enhances and corrects aberrant translation of poliovirus RNA in reticulocyte lysate J Virol 1993; 67:3798-3807.
90. Blyn LB, Swiderek KM, Richards O, Stahl DC, Semler BL, Ehrenfeld E. Poly(rC) binding protein 2 binds to stem-loop IV of the poliovirus RNA 5′ noncoding region: identification by automated liquid chromatography-tandem mass spectrometry Proc Natl Acad Sci U S A 1996; 93:11115-11120.
91. Blyn LB, Towner J, Semler BL, Ehrenfeld E. Requirement of poly(rC) binding protein 2 for translation of poliovirus RNA J Virol 1997; 71:6243-6246.
92. Hunt SL, Hsuan JJ, Totty N, Jackson RJ. Unr, a cellular cytoplasmic RNA-binding protein with five cold-shock domains, is required for internal initiation of translation of human rhinovirus RNA Genes & Dev 1999; 13:437-448.
93. Florez PM, Sessions O, Wagner E, Gromeier M, Garcia-Blanco M. RNAi-mediated PTB depletion reveals a requirement for picornavirus IRES-dependent translation and propagation J. Virology 2004 Submitted.
94. Witherell G, Gil A, Wimmer E. Interaction of polypyrimdine tract binding protein with the encephalomyocarditis virus mRNA internal ribosomal entry site Biochemistry 1993; 32: 8268-8275.
95. Niepmann M, Petersen A, Meyer K, Beck E. Functional involvement of polypyrimidine tract-binding protein in translation initiation complexes with the internal ribosome entry site of foot-and-mouth disease virus J Virol 1997; 71:8330-8339.
96. Chang KH, Brown EA, Lemon SM. Cell type-specific proteins which interact with the 5? nontranslated region of hepatitis A virus RNA J Virol 1993; 67:6716-6725.
97. Anwar A, Ali N, Tanveer R, Siddiqui A. Demonstration of functional requirement of polypyrimidine tract-binding protein by SELEX RNA during hepatitis C virus internal ribosome entry site-mediated translation initiation J Biol Chem 2000; 275: 34231-34235.
98. Huez I, Creancier L, Audigier S, Gensac MC, Prats AC, Prats H. Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA Mol Cell Biol 1998; 18:6178-6190.
99. Boussadia O, Niepmann M, Creancier L, Prats AC, Dautry F, Jacquemin-Sablon H. Unr is required in vivo for efficient initiation of translation from the internal ribosome entry site of both rhinovirus and poliovirus J Virol 2003; 77:3353-3359.
100. Pilipenko EV, Viktorova EG, Guest ST, Agol VI, Roos RP. Cellspecific proteins regulate viral RNA translation and virus-induced disease EMBO J 2001; 20:6899-6908.
101. Sabin AB. Oral poliovirus vaccine. History of its development and prospects for eradication of poliomyelitis JAMA 1965; 194: 872-876.
102. Nomoto A, Omata T, Toyoda H, Kuge S, Horie H, Kataoka Y, Genba Y, Nakano Y, Imura N. Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome Proc Natl Acad Sci U S A 1982; 79:5793-5797.
103. Omata T, Kohara M, Kuge S, Komatsu T, Abe S, Semler BL, Kameda A, Itoh H, Arita M, Wimmer E, Nomoto A. Genetic analysis of the attenuation phenotype of poliovirus type 1 J Virol 1986; 58:348-358.
104. Minor PD. Attenuation and reversion of the Sabin vaccine strains of poliovirus Dev Biol Stand 1993; 78:17-26.
105. Taffs RE, Chumakov KM, Rezapkin GV, Lu Z, Douthitt M, Dragunsky EM, Levenbook IS. Genetic stability and mutant selection in Sabin 2 strain of oral poliovirus vaccine grown under different cell culture conditions Virology 1995; 209: 366-373.
106. Dunn G, Begg NT, Cammack N, Minor PD. Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources J Med Virol 1990; 32: 92-95.
107. Duggal R, Cuconati A, Gromeier M, Wimmer E. Genetic recombination of poliovirus in a cell-free system Proc Natl Acad Sci U S A 1997; 94:13786-13791.
108. Georgescu MM, Balanant J, Macadam A, Otelea D, Combiescu M, Combiescu AA, Crainic R, Delpeyroux F. Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic polio- myelitis J Virol 1997; 71:7758-7768.
109. Gromeier M, Wimmer E, Gorbalenya A. Genetics, pathogene- sis and evolution of picornaviruses. In: Domingo E, Webster R, Holland JJ, Eds. Origin and Evolution of Viruses, Academic Press. 1999:287-344.